Lipopolysaccharide signal transduction, regulation of tumor necrosis factor biosynthesis, and signaling by tumor necrosis factor itself

Journal of Cardiovascular Pharmacology

Volumn 25, Issue , 1995, Pages S1-S8

  Beutler, B ^a   Kruys, V ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Hypotension; Lipopolysaccharide; Septic shock; Tumor necrosis factor

Indexed keywords

CYTOKINE; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL MODEL; BIOSYNTHESIS; CONFERENCE PAPER; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYPOTENSION; MEDIATOR RELEASE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA TRANSLATION; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LIPOPOLYSACCHARIDES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029554196     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199500252-00002     Document Type: Article

References (65)

1. Morrison DC, Ryan JL. Bacterial endotoxins and host immune responses. Adv Immunol 1979;28:293-450.
2. Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol 1978;93:526-617.
3. Raschke WC, Baird S, Ralph P, Nakoinz I. Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 1978;15:261-7.
4. Tannebaum CS, Koerner TJ, Jansen MM, Hamilton TA. Characterization of lipopolysaccharide-induced macrophage gene expression. J Immunol 1988;140:3640-5.
5. Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, Mergenhagen SE. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 1980;141:55-63.
6. Freudenberg MA, Keppler D, Galanos C. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun 1986;51:891-5.
7. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985;161:984-95.
8. Beutler B, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985;135:3872-7.
9. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
10. Beutler B, Milsark IW, Cerami A. Passive immunization against cachectin/tumor necrosis factor (TNF) protects mice from the lethal effect of endotoxin. Science 1985;229:869-71.
11. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-9.
12. Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci USA 1994;91:215-9.
13. Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA 1991;88:10535-9.
14. Kruys V, Thompson P, Beutler B. Extinction of the tumor necrosis factor locus, and of genes encoding the lipopolysacchride signaling pathway. J Exp Med 1993;177:1383-90.
15. Sultzer BM. Genetic control of leucocyte responses to endotoxin. Nature 1968;219:1253-4.
16. Rosenstreich DL, Vogel SN, Jacques AR, Wahl LM, Oppenheim JJ. Macrophage sensitivity to endotoxin. Genetic control by a single codominant gene. J Immunol 1978;121:1664-70.
17. Watson J, Kelly K, Largen M, Taylor BA. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J Immunol 1978;120:422-4.
18. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986;232:977-80.
19. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, Jongeneel CV. KappaB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J Exp Med 1990;171:35-47.
20. Caput D, Beutler B, Hartog K, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA 1986;83:1670-4.
21. Shaw G, Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986;46:659-67.
22. Kruys V, Wathelet M, Poupart P, et al. The 3' untranslated region of the human interferon-β mRNA has an inhibitory effect on translation. Proc Natl Acad Sci USA 1987;84:6030-4.
23. Kruys VI, Wathelet MG, Huez GA. Identification of a translation inhibitory element (TIE) in the 3' untranslated region of the human interferon-β mRNA. Gene 1988;72:191-200.
24. Kruys V, Marinx O, Shaw G, Deschamps J, Huez G. Translational blockade imposed by cytokine-derived UA-rich sequences. Science 1989;245:852-5.
25. Han J, Brown T, Beutler B. Endotoxin-responsive sequences control cachectin/TNF biosynthesis at the translational level. J Exp Med 1990;171:465-75.
26. Han J, Beutler B. The essential role of the UA-rich sequence in endotoxin-induced cachectin/TNF synthesis. Eur Cytokine Netw 1990;1:71-5.
27. Han J, Huez G, Beutler B. Interactive effects of the TNF promoter and 3'-untranslated regions. J Immunol 1991;146:1843-8.
28. Beutler B, Brown T. A CAT reporter construct allows ultrasensitive estimation of TNF synthesis, and suggests that the TNF gene has been silenced in non-macrophage cell lines. J Clin Invest 1991;87:1336-44.
29. Han J, Lee J-D, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265:808-11.
30. Han J, Lee J-D, Tobias PS, Ulevitch RJ. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD 14. J Biol Chem 1993;268:25009-14.
31. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46.
32. Young P, McDonnell P, Dunnington D, Hand A, Laydon J, Lee J. Pyridinyl imidazoles inhibit IL-1 and TNF production at the protein level. Agents Actions 1993;39(suppl C):C67-9.
33. Geppert TD, Whitehurst CE, Thompson P, Beutler B. LPS signals activation of TNF biosynthesis through the RAS/RAF-1/MEK/MAPK pathway. Mol Med 1994;1:93-103.
34. Li S, Sedivy JM. Raf-1 protein kinase activates the NF-kappaB transcription factor by dissociating the cytoplasmic NF-kappaB-IkappaB complex. Proc Natl Acad Sci USA 1993;90:9247-51.
35. Kruys V, Saad A, Mijatovic T, Huez G. Identification of a TNF mRNA binding protein; regulation of its binding ability by lipopolysaccharides. Cir Shock (in press).
36. Sprang SR, Eck MJ. The 3-D Structure of TNF. In: Beutler B, ed. Tumor necrosis factors: the molecules and their emerging role in medicine. New York: Raven Press; 1992:11-32.
37. Eck MJ, Sprang SR. The structure of tumor necrosis factor-α at 2.6A resolution: implications for receptor binding. J Biol Chem 1989;264:17595-605.
38. Jones EY, Stuart DI, Walker NPC. Structure of tumor necrosis factor. Nature 1989;338:225-8.
39. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53:45-53.
40. Cseh K, Beutler B. Alternative cleavage of the cachectin/TNF propeptide results in a larger, inactive form of secreted protein. J Biol Chem 1989;264:16256-60.
41. McGeehan GM, Becherer JD, Bast RC Jr, et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994;370:558-61.
42. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994;370:555-7.
43. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-20.
44. Bazzoni F, Kruys V, Shakhov A, Jongeneel CV, Beutler B. Analysis of tumor necrosis factor promoter responses to ultraviolet light. J Clin Invest 1994;93:56-62.
45. Harel Y, Silva M, Giroir B, Weinberg A, Cleary TB, Beutler B. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by Shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest 1993;92:2110-6.
46. Rink L, Nicklas W, Alvarez-Ossorio L, Koester M, Kirchner H. Differential induction of tumor necrosis factor α in murine and human leukocytes by Mycoplasma arthritidis-derived superantigen. Infect Immun 1994;62:462-7.
47. Matsuyama S, Koide Y, Yoshida TO. HLA class II molecule-mediated signal transduction mechanism responsible for the expression of interleukin-1β and tumor necrosis factor-α genes induced by a staphylococcal superantigen. Eur J Immunol 1993;23:3194-202.
48. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-6.
49. Giroir BP, Beutler B. Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock 1992;36:200-7.
50. Exley AR, Cohen J, Buurman W, et al. Monoclonal antibody to TNF in severe septic shock. Lancet 1990;335:1275-7.
51. Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
52. Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2762-6.
53. Peppel K, Beutler B. Biological properties of a recombinant TNF inhibitor. In: Levin J, Alving CR, Munford RS, Stütz PL, eds. Bacterial endotoxin: recognition and effector mechanisms. Vienna: Elsevier Science Publishers; 1993:447-54.
54. Beutler B, Van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994;264:667-8.
55. Engelmann H, Holtmann H, Brakebusch C, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 1990;265:14497-504.
56. B. Beutler, ed. Tumor necrosis factors: the molecules and their emerging role in medicine. New York: Raven Press; 1992:1-590.
57. Heller RA, Song K, Fan N, Chang DJ. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 1992;70:47-56.
58. Schulze-Osthoff K, Beyaert R, Vandevoorde V, Haegeman G, Fiers W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J 1993;12:3095-104.
59. Vanhaesebroeck B, Reed JC, De Valck D, et al. Effect of bcl-2 proto-oncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. Oncogene 1993;8:1075-81.
60. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor factor and interleukin-1 signaling. Cell 1994;77:325-8.
61. Rivas CI, Golde DW, Vera JC, Kolesnick RN. Involvement of the sphingomyelin pathway in autocrine tumor necrosis factor signaling for human immunodeficiency virus production in chronically infected HL-60 cells. Blood 1994;83:2191-7.
62. KB translocation in intact HL-60 cells. J Biol Chem 1993;268:20520-3.
63. Kronke M, Schutze S, Scheurich P, Pfizenmaier K. TNF signal transduction and TNF-responsive genes. Immunol Ser 1992;56:189-216.
64. KB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992;71:765-76.
65. Liu J, Mathias S, Yang Z, Kolesnick RN. Renaturation and tumor necrosis factor-α stimulation of a 97-kDa ceramide-activated protein kinase. J Biol Chem 1994;269:3047-52.